Multi-year collaboration where LabGenius will apply its ML-driven protein engineering platform, EVATM, to the optimization of therapeutic NANOBODY® proteins
LabGenius, a pioneer in the use of machine learning (ML) for protein engineering, today announced the signing of a multi-year research collaboration with Ablynx, a Sanofi company.
Under the terms of the agreement, the companies will undertake a project, in the area of inflammation, that combines LabGenius’ capabilities in ML, robotic automation and synthetic biology with Ablynx’s expertise in NANOBODY® heavy chain variable domains. Over the course of the collaboration, LabGenius will use its EVATM platform to deliver optimized NANOBODY® candidates. These molecules will then be progressed by Ablynx into further validation studies.
Dr James Field, CEO of LabGenius commented:
“We’re excited to be applying our ML-driven technology platform to support Ablynx in the optimization of novel NANOBODY® constructs. We’re hopeful that the fruits of this collaboration will ultimately have a positive impact on patients.”
Dr Edwin Moses, Chairman of LabGenius’ board and former CEO of Ablynx commented:
“Having had the pleasure of working with the Ablynx team in the past over many years, I am looking forward to this new collaboration that combines their world-leading expertise in NANOBODY® technology with LabGenius’ cutting-edge ML technology.”
Financial terms of the deal were not disclosed.
NANOBODY is a registered trademark of Ablynx N.V.
For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to AI-Techpark.com.